Evidence map›Paper›PMID 36410422›Full record

ArticleActa tropica2023

Effects of Schistosoma mansoni and praziquantel treatment on the lower gastrointestinal mucosa: A cohort study in Tanzania.

Khanh Pham, Gideon S Mtalitinya, Christine Aristide, Efeose A Airewele, Deborah K Nyakaru, Paige McMahon, Gerald Mulaki Mulaki, Paul L A M Corstjens, Claudia J de Dood, Govert J van Dam and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Acta tropica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 3 countries.

Khanh PhamDivision of Infectious Diseases, Weill Cornell Medicine, New York, NY, USA. Electronic address: khp9007@med.cornell.edu.
Gideon S MtalitinyaAga Khan Hospital, Mwanza, Tanzania.
Christine AristideCenter for Global Health, Weill Cornell Medicine, New York, NY, USA.
Efeose A AireweleCenter for Global Health, Weill Cornell Medicine, New York, NY, USA.
Deborah K NyakaruCenter for Global Health, Weill Cornell Medicine, New York, NY, USA.
Paige McMahonCenter for Global Health, Weill Cornell Medicine, New York, NY, USA.
Gerald Mulaki MulakiNational Institute for Medical Research Health Center, Mwanza, Tanzania.
Paul L A M CorstjensDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands.
Claudia J de DoodDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands.
Govert J van DamDepartment of Parasitology, Leiden University Medical Center, Leiden, the Netherlands.
John M ChangaluchaMwanza Intervention Trials Unit, Mwanza, Tanzania.
Humphrey D MazigoDepartment of Parasitology, Catholic University of Health and Allied Sciences, Mwanza, Tanzania.
Myung Hee LeeCenter for Global Health, Weill Cornell Medicine, New York, NY, USA.
Hyasinta JakaDepartment of Internal Medicine, Catholic University of Health and Allied Sciences, Mwanza, Tanzania; Department of Internal Medicine, Mwanza College of Health and Allied Sciences, Mwanza, Tanzania.
Jennifer A DownsCenter for Global Health, Weill Cornell Medicine, New York, NY, USA; Weill Bugando School of Medicine, Mwanza, Tanzania.
Cornell University · USLeiden University Medical Center · NLCatholic University of Health and Allied Sciences · TZAga Khan Hospital Dar es Salaam · TZMwanza Intervention Trials Unit · TZNational Institute for Medical Research · TZ

Funding

Disparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2M
Clinical and Translational Science CenterUL1TR000457 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI IMPERATO-MCGINLEY, JULIANNE L · 2012 to 2016
$46.0M
T32: Pathogenesis of Infectious Diseases Training ProgramT32AI007613 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI ROY M. GULICK · 1999 to 2026
$8.8M
Doris Duke Charitable Foundation 2017067NCATS NIH HHS UL1 TR000457NCATS NIH HHS UL1 TR002384NIAID NIH HHS T32 AI007613
6 · The paper itself

Abstract

Schistosomes infect over 200 million people worldwide, but few studies have characterized the effects of Schistosoma mansoni infection and effective treatment on the lower gastrointestinal mucosa. In this prospective cohort study, we compared the clinical findings on sigmoidoscopy and laboratory measures in Tanzanian adults with and without S. mansoni infection at baseline and 6 months after praziquantel treatment. Grading of the endoscopic findings was done using the Mayo Scoring System for Assessment of Ulcerative Colitis Activity. Schistosome infection was confirmed by stool microscopy and serum circulating anodic antigen (CAA). Baseline comparisons were performed in Stata using Fisher's exact and Wilcoxon rank-sum tests, and pre- and post-treatment comparisons using Wilcoxon matched-pairs signed-rank and McNemar's tests. We investigated the clinical characteristics of 48 individuals: 32 with and 16 without S. mansoni infection. Infected individuals had greater severity of sigmoid and rectal mucosal abnormalities and higher Mayo scores and serum eosinophils (all p < 0.05) than uninfected individuals at initial evaluation. At 6 months, 28 individuals completed repeat blood tests and sigmoidoscopy. Of these, 14 cleared their baseline infection (n = 7) or experienced a greater than 7-fold decrease in serum CAA (n = 7). Follow-up sigmoidoscopies revealed some improvements in sigmoid and rectal mucosal findings, although Mayo scores were not significantly lower. Both the median erythrocyte sedimentation rates (32.5→12.5 mm/hr) and percent of eosinophils (7.1→3.1%) decreased in this group from baseline to follow-up. S. mansoni infection was associated with mild-to-moderate lower gastrointestinal mucosal abnormalities that were grossly visible during sigmoidoscopy, and these improved partially 6 months after effective treatment with praziquantel. Additional studies, of longer duration and focused on both clinical and mucosal immunologic effects of S. mansoni, could provide additional insight.

Indexed as

AnthelminticsSchistosomiasis mansoniAdultAnimalsCohort StudiesHumansMucous MembranePraziquantelProspective StudiesSchistosoma mansoniTanzaniaAnthelminticsPraziquantelGastrointestinal tractPraziquantelSchistosoma mansoniSigmoidoscopy

Identifiers

PMID36410422
PMCPMC9884117
OpenAlexW4309364684

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.